biotech · Acute Respiratory Distress Syndrome (ARDS) · Allergic Contact Dermatitis · EDSA
Edesa Biotech
Edesa Biotech is a biotech organization headquartered in Markham, CA. It trades on NYSE under ticker EDSA. Primary therapeutic focus areas include Acute Respiratory Distress Syndrome (ARDS), Allergic Contact Dermatitis,
Markham, CA HQ
2015 Founded
22 Employees
Public company Type
EDSA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Markham, CA
- Founded
- 2015
- Employees
- 22
- Programs
- 5
- Drugs
- 5
- Patents
- 0
Cohort C: bevacizumab
Phase 2 · small molecule · Acute Respiratory Distress Syndrome (ARDS)
Cohort C: bevacizumab for Acute Respiratory Distress Syndrome (ARDS) is a Phase 2 program (small_molecule) at Edesa Biotech with 1 ClinicalTrials.gov record(s).
Internal code BP-ARDS-P2-001 (bevacizumab)
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Edesa Biotech
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Acute Respiratory Distress Syndrome (ARDS)
- Status
- active
- Trials
- 1